Basic Information
Mektovi
Regulatory Information
EMEA/H/C/004579
September 20, 2018
11
December 10, 2024
Company Information
France
Les Cauquillous 81500 - Lavaur
PIERRE FABRE MEDICAMENT
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Melanoma Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Non-small cell lung cancer (NSCLC) Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
Overview Summary
Mektovi is a medicine used in adults for treating certain cancers when their cells have a mutation (change) in their genes called 'BRAF V600'. Mektovi is used in combination with another medicine, encorafenib , to treat: - melanoma (a skin cancer) that has spread or cannot be removed by surgery; - a type of lung cancer called non-small cell lung cancer (NSCLC). It is used when the cancer is advanced and has the BRAF V600E version of the mutation. Mektovi contains the active substance binimetinib.